Daniel Petree
Director/Board Member at SUTRO BIOPHARMA, INC.
Net worth: 76 803 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Connie Matsui | F | 70 |
Stanford University
| 5 years |
| William Newell | M | 66 |
The University of Michigan Law School
| 19 years |
| Jane Chung | F | 53 | 3 years | |
| Jay Birnbaum | M | 79 |
Lipidio Pharmaceuticals, Inc.
 Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Nicki Vasquez | M | 61 | 9 years | |
| Jon Wigginton | M | 62 | 4 years | |
| Heidi Hunter | F | 66 | 3 years | |
| Henry Heinsohn | M | - | - | |
| James Panek | M | 71 | 4 years | |
| Michael Dybbs | M | 49 | 6 years | |
| Frederick J. Ruegsegger | M | 68 |
Four Oaks Partners LLC
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | 16 years |
| Linda Fitzpatrick | F | 67 | 16 years | |
| John Freund | M | 70 | 10 years | |
| Edward Albini | M | 66 | 11 years | |
| Joseph Lobacki | M | 65 | 7 years | |
| John Gordon Foulkes | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| James A. Spudich | M | 82 |
Stanford University
| 47 years |
| David A. Bullough | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Anne Borgman | M | 56 | 1 years | |
| Curtis B. Eaves | M | - |
Stanford University
| 49 years |
| John Shoven | M | 76 |
Stanford University
| 51 years |
| Nancy Hutson | M | 74 |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Hans-Peter Gerber | M | - | 1 years | |
| Raksha Shah | M | - |
Lipidio Pharmaceuticals, Inc.
Lipidio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lipidio Pharmaceuticals, Inc. develops and manufactures medicines. It focuses on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). The company was founded by Jay Edward Birnbaum and is headquartered San Diego, CA. | - |
| Craig Berman | M | - | 4 years | |
| Regina Cheng | F | - | 4 years | |
| Diana Landa | F | - | 4 years | |
| Carlos Lugo | M | - | - | |
| David Pauling | M | - | - | |
| Werner Rubas | M | - | 3 years | |
| Steve Michel | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Margaret Wilson | F | 86 | 14 years | |
| John P. Walker | M | 75 |
Four Oaks Partners LLC
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | 12 years |
| Sabrina Johnson | F | 57 |
Cypress Bioscience, Inc.
 Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 12 years |
| Rocky Barber | M | - |
Stanford University
| 6 years |
| Tsuneo Yahagi | M | 82 |
Stanford University
| 6 years |
| Bruce Gerhardt | M | 73 | 13 years | |
| David Holmes Williams | M | - |
Stanford University
| 5 years |
| David Hale | M | 75 | 11 years | |
| Scott R. Pancoast | M | 58 |
Lpath, Inc.
 Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | 16 years |
| Dennis M. Buede | M | - |
Stanford University
| 5 years |
| James Weisberger | M | 68 |
Stanford University
| 5 years |
| Chao Chun Lu | M | - |
Stanford University
| 4 years |
| Edward Unkart | M | 74 |
Stanford University
| 6 years |
| Pete Higgins | M | - |
Stanford University
| 7 years |
| Gary Kurtzman | M | 69 |
Stanford University
| 4 years |
| Annette C. North | F | 58 |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | 1 years |
| Vince Vannelli | M | - |
Stanford University
| 5 years |
| Julian Nikolchev | M | 70 |
Stanford University
| 5 years |
| Richard M. Swanson | M | 78 |
Stanford University
| 19 years |
| Elaine Kant | M | - |
Stanford University
| 5 years |
| Marie L. Fiala | F | - |
Stanford University
| 7 years |
| Skip Rung | M | - |
Stanford University
| 4 years |
| Bill Berg | M | 70 |
Stanford University
| 5 years |
| Yan Hok Fan | M | 74 |
Stanford University
| 4 years |
| R. Mark van Allen | M | - |
Stanford University
| 9 years |
| Mark Williams | M | 70 |
Stanford University
| 4 years |
| Ted Meyer | M | - |
Stanford University
| 6 years |
| Peter Salovey | M | 66 |
Stanford University
| 4 years |
| Shlomo Shamir | M | 76 |
Stanford University
| 3 years |
| Abdullah Atalar | M | 70 |
Stanford University
| 3 years |
| Christopher Walt | M | - |
Stanford University
| 5 years |
| Everett Cox | M | - |
Stanford University
| 5 years |
| Grant E. Finlayson | M | - |
Stanford University
| 6 years |
| Terry A. Bresnick | M | - |
Stanford University
| 5 years |
| Michael P. Bohrer | M | - |
Stanford University
| 4 years |
| Ivor Royston | M | 79 | 13 years | |
| Andrew Lanza | M | 67 |
Stanford University
| 5 years |
| Robert E. Marks | M | 72 |
Stanford University
| 5 years |
| Robert D. Caligiuri | M | 72 |
Stanford University
| 4 years |
| Lyle J. Arnold | M | 77 | 11 years | |
| David S. Lobel | M | - |
Stanford University
| 2 years |
| Jeffrey Allen Ferrell | M | 49 |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | 9 years |
| Jeffrey Meckler | M | 57 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 1 years |
| Sookap Hahn | M | 75 |
Stanford University
| 4 years |
| John F. Shoch | M | - |
Stanford University
| 3 years |
| Mike L. Foster | M | - |
Stanford University
| 9 years |
| Valerie Jarrett | F | 67 |
The University of Michigan Law School
Stanford University
| 7 years |
| Dan Kisner | M | 77 |
Lpath, Inc.
Lpath, Inc. BiotechnologyHealth Technology Lpath, Inc. operates as a biotechnology company, which focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. It develops three drug candidates, each of them into clinical trials, and built evidence to support their approach of targeting bioactive lipids to treat a wide range of diseases. The company was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA. | 4 years |
| Thurman Rodgers | M | 76 |
Stanford University
| 3 years |
| R. Gendreau | M | 68 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 30 years |
| Abbas El Gamal | M | - |
Stanford University
| 3 years |
| Jean-Lou Chameau | M | 71 |
Stanford University
| 4 years |
| Brad Mills Mills | M | 68 |
Stanford University
| 6 years |
| Nick Sargen | M | - |
Stanford University
| 9 years |
| Timothy Saxe | M | 68 |
Stanford University
| 5 years |
| Robert W. Baldridge | M | 89 |
TSI Corp
| 1 years |
| George Hutton | M | 69 |
Stanford University
| 5 years |
| Oliver E. Buckley | M | - |
Stanford University
| 7 years |
| Jean-Michel Valette | M | 63 |
Stanford University
| 5 years |
| Howard Roy Gleicher | M | - |
Stanford University
| 5 years |
| Stephan R. Peers | M | 72 |
Stanford University
| 4 years |
| Kurt Richard Jaggers | M | 66 |
Stanford University
| 4 years |
| Stephen Wurzburg | M | - |
Stanford University
| 5 years |
| Kim Mitchell | M | 73 |
Stanford University
| 4 years |
| Glenn Prestwich | M | - |
Stanford University
| 3 years |
| Glenn Anderson | M | 71 |
Stanford University
| 4 years |
| Peter J. Courture | M | - |
Stanford University
| 3 years |
| David Alan Ward | M | - |
Stanford University
| 4 years |
| Jeffrey Kerns | M | 67 |
Stanford University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel Petree
- Personal Network
